BSX vs EW — Key Metrics
| Metric | BSX (BOSTON SCIENTIFIC CORP) | EW (EDWARDS LIFESCIENCES CORP) |
|---|---|---|
| Price | 43.64 | 105.23 |
| Market Cap | 63.26 Billion | 60.51 Billion |
| P/E (TTM) | 18.34 | 59.45 |
| P/B (Quarterly) | 2.506 | 5.261 |
| P/S (TTM) | 3.0 | 9.07 |
| Net Profit Margin (TTM) | 16.6 | 15.3 |
| Gross Margin (TTM) | 69.1 | 78.0 |
| ROE (TTM) | 13.9 | 9.7 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Recommendation Summary
Stock BSX is projected to greatly outperform the market, stock EW is projected to underperform the market. Upfront Recommendation: BSX.
Financial Metrics
| BSX | Metrics | EW |
|---|---|---|
| $43.64 | Price | $105.23 |
| — | Market Capitalization | — |
| 18.34 | Price to Earnings Ratio | 59.45 |
| 3.0 | Price to Sales | 9.07 |
| 18.99 | Price to FCF Ratio | 42.49 |
| 4.34 | Price to Gross Profit | 11.62 |
| 29.3 | Price to R&D | 55.45 |
| 7.75 | Price to Current Assets | 8.35 |
BSX vs EW at a glance
Boston Scientific Corp (BSX) and Edwards Lifesciences Corp (EW) are both Medical Devices companies in the Healthcare sector. They are similar in size: $63.3 billion and $60.5 billion in market value.
On trailing-twelve-month figures, BSX trades at 18.3 times trailing earnings and EW at 59.5; net profit margins are 16.6% and 15.3%.
The Upfront Investment model currently rates BSX Greatly Outperform and EW Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.